News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Immunotherapy uses invisibility cloak to deliver direct hit to prostate cancer
A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports.
.jpg?sfvrsn=205a5de0_2 "Castration resistant prostate cancer cells stained for a number of key driver molecules. (Mateus Crespo, Gerhardt Attard and Johann de Bono / the ICR, 2012)")
Targeted radiotherapy injection shrinks treatment-resistant prostate cancer tumours in early clinical trial
A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports.
ICR welcomes NICE recommendation of talazoparib for advanced prostate cancer
The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in combination with enzalutamide, for adults with prostate cancer that has spread.
The ICR welcomes NHS decision to grant lifesaving prostate cancer drug to men in England
The Institute of Cancer Research, London, has welcomed the announcement that the lifesaving drug abiraterone has been approved for use on the NHS for men in England with prostate cancer that has a high risk of spreading.
Blood test could spare men with advanced prostate cancer from futile chemotherapy
New research has identified a way to predict resistance to a cancer drug commonly used to treat advanced prostate cancer.
New AI models set to revolutionise medical imaging and transform cancer care
Two ground-breaking studies have demonstrated that combining artificial intelligence (AI) with state-of-the-art MRI imaging could revolutionise how clinicians detect, monitor and treat advanced prostate cancer.
ICR responds to announcement of prostate cancer screening for men with BRCA1 and BRCA2 gene mutations
Experts at The Institute of Cancer Research, London, have responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme for men with a confirmed BRCA1 and BRCA2 variant.
First men invited to take part in the most ambitious prostate cancer trial in decades
Today, the first men have been invited to join the ambitious £42 million TRANSFORM screening trial, kicking off the biggest prostate cancer screening study in a generation.
Legendary jockey Bob Champion awarded honorary doctorate at ICR graduation ceremony
Legendary jockey Bob Champion has been awarded an honorary doctorate by The Institute of Cancer Research, London, in recognition of his outstanding contribution in supporting research into male cancers at a ceremony at London’s Guildhall.
Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening
Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, experts are urging.
New drug combination to tackle advanced prostate cancer
Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research.
Stress may increase cancer risk in people with inherited cancer genes
Suffering from psychological stress could further increase cancer risk in those already genetically predisposed to the disease, according to new research.
